BIOLOGY.DIGITAL
FDA Issues Updated 2026 Regulatory Framework for AI and Machine Learning in Drug and Biologics Submissions

Image: FDA CDER

Regulation

FDA Issues Updated 2026 Regulatory Framework for AI and Machine Learning in Drug and Biologics Submissions

November 16, 2026 • Source: FDA CDER

The US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and CBER published updated 2026 risk-based credibility assessment guidelines for AI/ML models used in IND and BLA submissions.

**Executive Summary (2026-11-16):** The US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and CBER published updated 2026 risk-based credibility assessment guidelines for AI/ML models used in IND and BLA submissions. Source: FDA CDER.

Technical Architecture & R&D Impact

Having reviewed over 500 regulatory submissions incorporating AI/ML across target qualification, quantitative systems pharmacology (QSP), digital pathology biomarkers, and CMC process control, the FDA framework defines Context of Use (CoU) validation tiers and 21 CFR Part 11 data provenance requirements.

Enterprise Biopharma Procurement Takeaways

For computational biology leads, medicinal chemists, and R&D IT architects, this milestone underscores the rapid convergence of wet-lab experimental validation and scalable cloud foundation models during H2 2026. Teams evaluating vendors in the Regulation category should benchmark API reproducibility, GxP audit readiness, and zero-data-retention VPC deployment terms.

Related Products

Published November 16, 2026

More News

Last updated: November 16, 2026

Ask AI